What it's for (Indications)
- Oxytocin, a synthetic posterior pituitary hormone, is primarily indicated for its potent uterotonic effects in various obstetric scenarios.
- Its principal uses include the induction of labor, which is medically initiated when the benefits of delivery outweigh the risks of continuing the pregnancy.
- Conditions necessitating labor induction may include post-term pregnancy, pre-eclampsia, gestational diabetes, chorioamnionitis, premature rupture of membranes without spontaneous labor, or fetal growth restriction.
- Secondly, oxytocin is widely utilized for the augmentation of labor when uterine contractions are deemed inadequate in frequency, intensity, or duration to achieve satisfactory cervical dilation and fetal descent during the active phase of labor.
- This helps to overcome hypotonic uterine dysfunction.
- A critical indication is the prevention and treatment of postpartum hemorrhage (PPH) following placental expulsion.
- Administered proactively or reactively, oxytocin effectively promotes sustained uterine contraction and involution, thereby compressing intramyometrial blood vessels and significantly reducing blood loss, which is a leading cause of maternal morbidity and mortality worldwide.
- Less frequently, oxytocin has been used in a diagnostic capacity, such as in the oxytocin challenge test (fetal stress test) to assess uteroplacental function, though this has largely been superseded by other methods.
- Its use mandates careful patient selection and continuous monitoring due to its profound physiological effects on the uterus and potential risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration. Dosage is determined by uterine response, must be individualized, and initiated at a very low level. Intravenous infusion (drip method) is the only acceptable parenteral administration method for induction or stimulation of labor. Accurate control of the infusion rate, preferably with an infusion pump, is essential. It is convenient to piggyback the oxytocin infusion on a physiologic electrolyte solution to allow abrupt cessation of oxytocin without interrupting the electrolyte infusion. |
Safety & Warnings
Common Side Effects
- Patients may experience anti-diuretic effects including water intoxication (potentially severe with convulsions, coma, and maternal death), headaches, and nausea, especially with prolonged or rapid infusion.
- Other reported maternal adverse reactions include anaphylactic reaction, premature ventricular contractions, postpartum hemorrhage, pelvic hematoma, cardiac arrhythmia, subarachnoid hemorrhage, fatal afibrinogenemia, hypertensive episodes, vomiting, uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus (especially with excessive dosage or hypersensitivity).
- Fetal or neonatal adverse reactions due to induced uterine motility include bradycardia, low Apgar scores at five minutes, and premature ventricular contractions.
Serious Warnings
- Black Box Warning: IMPORTANT NOTICE: Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin (oxytocin) is not indicated for elective induction of labor.
- Accurate control of the intravenous infusion rate is essential.
- The possibility of increased blood loss and afibrinogenemia should be considered.
- This medication should not be used for general pregnancy outside of indicated labor induction or stimulation.
- Lactating individuals should consult their doctor before use.
- Patients should avoid driving and consuming alcohol while taking this medicine as it may affect their ability to drive.
How it Works (Mechanism of Action)
Oxytocin exerts its physiological and pharmacological effects by binding to specific oxytocin receptors (OTRs), which are G-protein coupled receptors highly expressed on the smooth muscle cells of the myometrium and the myoepithelial cells of the mammary glands. The density and sensitivity of these receptors in the uterus significantly increase during pregnancy, reaching peak levels at term and during labor, rendering the uterus highly responsive to oxytocin. Upon binding, oxytocin activates the Gq protein coupled signaling pathway, leading to the activation of phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium ions (Ca2+) from intracellular stores, particularly the sarcoplasmic reticulum. The subsequent increase in intracellular Ca2+ concentration is the primary event that initiates and sustains uterine smooth muscle contraction by facilitating the interaction between actin and myosin filaments. Furthermore, Ca2+ influx through voltage-gated channels is also enhanced. DAG, along with Ca2+, activates protein kinase C, contributing to the contractile process. Oxytocin also stimulates the synthesis and release of prostaglandins from the decidua, which further potentiate uterine contractions and contribute to cervical ripening. In the mammary glands, oxytocin causes the contraction of myoepithelial cells surrounding the alveoli, leading to the ejection of milk (the 'milk let-down' reflex).